Citius Oncology (CTOR) Enterprise Value (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Enterprise Value data on file, last reported at -$2.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 2350466.07% year-over-year to -$2.6 million in Q1 2026; TTM through Mar 2026 was -$2.6 million, a 2350466.07% decrease from a year earlier, with the FY2025 full-year figure at -$3.9 million, down 3504282.14% from the prior year.
• Enterprise Value for Q1 2026 stood at -$2.6 million, up from -$7.3 million in the prior quarter.
• Over the last five years, Enterprise Value for CTOR reached as high as -$112.0 in Q3 2024 and fell as low as -$7.3 million in Q4 2025.
• Historically, Enterprise Value has averaged -$1.2 million across 5 years, with a median of -$76853.0 in 2023.
• On a YoY basis, Enterprise Value climbed as much as 99.66% in 2025 and fell as far as 6513695.54% in 2025.
• Year by year, Enterprise Value stood at -$289175.0 in 2022, then surged by 88.68% to -$32746.0 in 2023, then jumped by 99.66% to -$112.0 in 2024, then plunged by 6513695.54% to -$7.3 million in 2025, then soared by 63.91% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$2.6 million in Q1 2026, -$7.3 million in Q4 2025, and -$3.9 million in Q3 2025.